TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05247203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
Study: NCT05810519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active break with the proposed lumbar and hip extension exercises
Description: Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting. In the experimental intervention, the exercise program include exercises and will be based on patient education. The participants will also explain the importance of regular training and receive a booklet with photographed and described exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care recommendations
Description: Participants assigned to the control group will receive an educational self-care book containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. The control group will perform their regular baseline activities.
Study: NCT00057161

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Coordinated Representative Payeeship with Case Management
Study: NCT06400667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper limb Kinematic Assessment with Optoelectronic system
Description: All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks. During the data acquisition protocol, the subject perform five trial for each upper limb of a determinate functional task for each session. Every subject repeat this operations 2 times with 2 different operators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper limb Kinematic Assessment with Optoelectronic system
Description: All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks. During the data acquisition protocol, the subject perform five trial for each upper limb of a determinate functional task for each session. Every subject repeat this operations 2 times with 2 different operators.
Study: NCT04790786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lilly Bamlanivimab
Description: Administration of Lilly Bamlanivimab to COVID positive patients
Study: NCT05425485

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-component intervention
Description: Web-based strategy with processes, materials, and patient and doctor education formats.
Study: NCT05146167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bodhi AIM (intervention group)
Description: Bodhi AIM (Action In Mindfulness) is a smartphone-based app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations (e.g., attending a party).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIB (control group)
Description: HIB (Health In Balance) is a smartphone-based app that is matched to Bodhi AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in Bodhi AIM. Like Bodhi AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts.
Study: NCT06405230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed+ (carboplatin or cisplatin)
Description: PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed+ (carboplatin or cisplatin)
Description: PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered.
Study: NCT04790786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regeneron Casirivimab + Imdevimab
Description: Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lilly Bamlanivimab + Etesevimab
Description: Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Administration of Sotrovimab to COVID positive patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bebtelovimab
Description: Administration of Bebtelovimab to COVID positive patients
Study: NCT05656157

Intervention type: DEVICE
Intervention: Medical device
Description: Clinical decision support system
Study: NCT06206863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in virtual exercise classes
Study: NCT06467448

Intervention type: DEVICE
Intervention: EMG Assessement of Recovery of Neuromuscular Function
Description: EMG Train of Four Assessment of Recovery of Neuromuscular Function

Intervention type: DEVICE
Intervention: EMG Assessement of Recovery of Neuromuscular Function
Description: EMG Train of Four Assessment of Recovery of Neuromuscular Function
Study: NCT06206863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05544084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator Approach
Description: Patient navigators in collaboration with community health workers will work with women eligible for cervical cancer screening to overcome intrapersonal and community level barriers to screening in order to engage early with the health system for cervical cancer screening and follow-up of positive screens. Their support can help patients get the cancer screenings and follow-up care they need, while addressing prevalent gender inequities and community-level stigma associated with cancer within the Senegal context.
Study: NCT05326217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise :In this study, the exercise intensity is set based on the subject's maximum heart rate, and the target heart rate is adjusted according to the literature to reach 60-90% of the maximum heart rate. A gradual increase of intermittent exercise will be designed for current exercise prescription. In terms of exercise frequency and time, there will be two times interventions per week for at least 60 minutes per time (including warm-up and cool down exercises).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant exercise
Description: The resistant exercise : muscular endurance (15-20RM) and muscular hypertrophy (8-12RM) are applied to main exercise intensity. The intensity is gradually adjusted according to the state of each subject, and the intervention is performed twice a week (50 minutes per time).The target muscles of resistance training include quadriceps femoris, biceps femoris, calf muscles, core muscles (including pelvic floor muscles), back muscles, pectoralis major, biceps/triceps and other muscle groups.
Study: NCT04764994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo®Spring ((Task-oriented upper extremity rehabilitation system)
Description: Armeo®Spring is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The Armeo Spring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury or other neurological diseases and injuries. It combines an adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Program
Description: This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Program
Description: This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.
Study: NCT06465446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM01
Description: 2.0mg/kg, IV infusion
Study: NCT05603507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: training done with a pressure threshold-loading device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Circuit training of aerobic and resistive exercise

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: pulmonary rehabilitation
Description: Circuit training of aerobic and resistive exercise
Study: NCT04953117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB of Lepu Medical(dimeter≥2.00 mm)
Description: subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restore DEB
Description: subjects receiving Restore DEB

Intervention type: DEVICE
Group type: OTHER
Intervention: DCB of Lepu Medical(dimeter<2.00 mm)
Description: subjects receiving DCB of Lepu Medical(dimeter\<2.00 mm)
Study: NCT04946630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PreciseInhale
Description: Three different settings of the medical device PreciseInhale will be used in the study; PreciseInhale Whole Lung Exposure, PreciseInhale Bronchial Bolus/Breath hold Exposure and PreciseInhale Alveolar Bolus/Breath hold Exposure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PreciseInhale
Description: Three different settings of the medical device PreciseInhale will be used in the study; PreciseInhale Whole Lung Exposure, PreciseInhale Bronchial Bolus/Breath hold Exposure and PreciseInhale Alveolar Bolus/Breath hold Exposure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PreciseInhale
Description: Three different settings of the medical device PreciseInhale will be used in the study; PreciseInhale Whole Lung Exposure, PreciseInhale Bronchial Bolus/Breath hold Exposure and PreciseInhale Alveolar Bolus/Breath hold Exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seretide Evohaler forte
Description: Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.
Study: NCT06465446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study: NCT06013072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Experimental
Description: Combination of pre-probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: Placebo
Description: Inert compound
Study: NCT05574452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction using the SONAR Femoral Aimer PSI
Description: ACL reconstruction using the SONAR Femoral Aimer PSI
Study: NCT05543330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M701 pleural infusion
Description: M701 pleural infusion on Days 1,4,7 and 10.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pleural drainage
Description: Pleural effusion drainage via Ultra-sound guidance on Day 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleural drainage
Description: Pleural effusion drainage via Ultra-sound guidance on Day 1.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cisplatin pleural infusion
Description: Cisplatin pleural infusion (30-50mg/m2) on Day 1.
Study: NCT04877652

Intervention type: OTHER
Intervention: Standard of care
Description: Standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
Study: NCT04773678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous (SC) injection.
Study: NCT05045469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dian dao san
Description: dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dian dao san
Description: dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks
Study: NCT06079775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeruborbactam Oral Prodrug
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: Experimental

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xeruborbactam Oral Prodrug Placebo
Description: Placebo Comparator
Study: NCT04773678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous (SC) injection.
Study: NCT05264844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masking tape
Description: IV catheters will be fixed with masking tape
Study: NCT06674538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moonshot antibodies
Description: Chimeric antibodies
Study: NCT06335628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geistlich Fibro-Gide®
Description: Geistlich Fibro-Gide® is intended to be used as an implantable device for regeneration and augmentation of soft tissue in oral and maxillofacial surgery.
Study: NCT06277141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard message
Description: Participants will receive standard messaging based on the Cancer Association of South Africa (CANSA) recommendation on breast cancer screening and a reminder to screen for breast cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radiology booking site link.
Description: Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radiology practice telephone numbers
Description: Participants will receive a reminder to screen for breast cancer together with a list and telephone numbers of radiology practices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radiology site link and telephone numbers
Description: Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site and a list and telephone numbers of radiology practices
Study: NCT06348056

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 30 mg Zn Amino Acid daily for 13 days
Description: A 30 mg zinc amino acid supplement is taken p.o. in the fasted state for 13 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 30 mg Zn Gluconate daily for 13 days
Description: A 30 mg zinc gluconate supplement is taken p.o. in the fasted state for 13 days.
Study: NCT04586153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meplazumab for Injection
Description: humanized antibody target CD147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile normal saline (0.9%)
Description: Sterile normal saline (0.9%)
Study: NCT04690036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab injection
Description: when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.
Study: NCT05485220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise group: Peak workload will be determined by performing an exercise test on the patients. Training will be given at 60-70% of the peak workload for 45 minutes with an arm ergometer 3 days a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: High-intensity interval training Group: Peak workload will be determined by performing an exercise test on the patients and arm ergometer HIIT will be done with a total of 45 minutes, 90-95% of the peak workload for 30 seconds, 60 seconds in between, active recovery at 40-50% workload, 3 days a week for 8 weeks.
Study: NCT06079775

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ceftibuten Placebo
Description: Placebo Comparator
Study: NCT06473506

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saliva collection
Description: Self-collected saliva sample with molecular testing performed. Results are compared to rapid antigen testing, bacterial throat culture and bacterial throat molecular testing
Study: NCT04946630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seretide Evohaler forte
Description: Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.
Study: NCT04717141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective nerve block
Description: D0 :~* Information, collection of consent, inclusion,~* Clinical and instrumental evaluation,~* Realization of the selective nerve block,~* Post-selective nerve block clinical and instrumental re-evaluation,~* Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~- Clinical and instrumental post-botulinum toxin injection evaluation.
Study: NCT05950347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcutaneous auricular vagus nerve stimulation
Description: Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous auricular vagus nerve stimulation
Description: Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
Study: NCT05630170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-ECG
Description: A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.
Study: NCT04946630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seretide Evohaler forte
Description: Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seretide Evohaler forte
Description: Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.